Pharmaceuticals, Biotechnology and Life Sciences
Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, and AstraZeneca, have teamed up to develop an AI-powered tool to pre-screen...
ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an underwritten public offering and a concurrent registered direct offering of...
SLEEVER®, a French family-owned group International SME and innovative leader in shrinksleeve label technology, and CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, today unveil the first innovation...
World Food Safety Day is jointly facilitated by the Food and Agriculture Organization of the United Nations (FAO) and the...
The society is changing rapidly, millennials are now 40 years old people, and it's OK. The Gen-X folks are already...
Poster presentation highlights SMART adenine base editors (ABEs)small enough to be packaged into a single adeno-associated virus (AAV) Data demonstrate…
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage…
Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a…
Information regarding the total number of voting rights and total number of shares of the Company as of September 30,…
DALLAS, Oct. 14, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva”…
Ipsen is the first pharma company in the world to receive Shingo Prizes for two sites producing treatments for patientsIpsen’s…
TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group” or the “Company”) (CSE: PSYG) hereby announces that…
First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological…
Combined company to expand portfolio of clinical & commercial-stage assets in fertility, oncology, and autoimmune diseasesSARASOTA, Fla. and MIAMI, Oct.…
